

Amend C / #16  
PATENT  
910000-2020  
5.14.04AMENDMENTIn The Claims:

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows:

1. (Currently Amended) A method for treating a disorder characterized by excessive proliferation of tissue treatable by ~~an anti-angiogenic molecule~~ thrombospondin-2 (TSP-2) or a fragment thereof, in a subject in need thereof comprising implanting a cell-matrix structure, wherein said cell-matrix structure comprises a matrix having attached thereto cells that stably express ~~an anti-angiogenic molecule~~ TSP-2, or a fragment thereof wherein the fragment comprises at least 10 contiguous amino acids of either (a) a procollagen domain of TSP-2, or (b) a Type I repeat of TSP-2, in an amount effective to inhibit or regress the excessive tissue proliferation.
2. (Currently Amended) The method of claim 1 wherein the disorder is selected from the group consisting of malignant and benign neoplasias, vascular, inflammatory conditions causing excessive proliferation of cells, endometriosis, ~~congenital or endocrine abnormalities, psoriasis,~~ unwanted skin proliferation, ~~rheumatoid arthritis,~~ unwanted angiogenesis of the eye, restenosis, and infections causing excessive proliferation of cells.
3. (Original) The method of claim 1 wherein the matrix is selected from the group consisting of fibrous scaffolds, polymeric hydrogels, and micromachine or micromolded substrates.
4. (Original) The method of claim 1 wherein the cells are selected from the group consisting of fibroblasts, tissue specific cells, progenitor cells, and stem cells.
5. (Currently Amended) The method of claim 1 wherein the cells are genetically engineered to produce ~~the anti-angiogenic molecule~~ TSP-2 or a fragment thereof.

PATENT  
910000-2020

6. (Canceled)

7. (Currently Amended) The method of claim 1 wherein ~~the anti-angiogenic molecule~~ TSP-2 or a fragment thereof is endogenous to the cells on the matrix and the cells are engineered to increase expression of ~~the anti-angiogenic molecule~~ TSP-2 or a fragment thereof.

8-21. (Canceled)

22. (Currently Amended) The method of claim ~~16~~ 1 wherein the cells are of a different cell type than the tissue that has proliferated.

23. (Currently Amended) The method of claim ~~16~~ 1 wherein the cells are selected based on natural production of TSP-2 or a fragment thereof.

24-29. (Canceled)